Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 3, 2000, Pages 211-220

  Kurita, A ^a   Kado, S ^a   Kaneda, N ^a   Onoue, M ^a   Hashimoto, S ^a   Yokokura, T ^a  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

CPT 11; Delayed onset diarrhea; Irinotecan hydrochloride; Pharmacokinetics; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; ENZYME INHIBITION; INTESTINE EPITHELIUM; MITOSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILIARY TRACT; CAMPTOTHECIN; CECUM; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; GLUCURONATES; ILEUM; INTESTINAL MUCOSA; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033802541     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000151     Document Type: Article

References (49)

1. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
2. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
3. Identitication of metabolites of irinotecan, a new derivative of camptothecin, in the rat bile and its biliary excretion
4. 2-mediated secretory response to 5-hydroxytryptamine in the small intestine of rat in vivo
5. 2 on colonic motility in rabbits
6. Patterns of prostaglandin synthesis and degradation in isolated superficial and proliferative colonic epithelial cells compared to residual colon
7. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors
8. The S-phase cytotoxicity of camptothecin
9. Mobilization of peripheral blood stem cells in patients with advanced thoracic malignancies after irinotecan (CPT-11) administration
10. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
11. Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative
12. Antitumor activity of CPT-11 against rat Walker 256 carcinoma
13. CPT-11-induced cholinergic effects in cancer patients
14. A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11
15. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
16. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
17. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors
18. Nonlinear pharmacokinetics of CPT-11 in rats
19. Metabolism and pharmacokinetics of camptothecin analogue CPT-11 in the mouse
20. 2 and water absorption in the rat
21. Inhibitory effect of CPT-11, a derivative of camptothecin, on acetylcholinesterase, and its binding ability to acetylcholine receptors
22. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
23. Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes
24. Relationship between CPT-11 pharmacokinetics and diarrhea in the combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP)
25. Antitumor activity of 7-ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors
26. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid phase extraction system, PROSPEKT
27. +-ATPase activity and ouabain binding in MDCK cells
28. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
29. A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer
30. Cell cycle-dependent cytotoxicity of irinotecan hydrochloride in mice
31. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion
32. An early II phase study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma
33. Phase I and pharmacokinetic trial of CPT-11 in patients with refractory solid tumors
34. - secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon
35. Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11)
36. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment
37. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its metabolite SN-38
38. Effect of prostanoids on human intestinal Na-K-ATPase activity
39. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group
40. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer
41. Low-dose CPT-11 against a recurrent rectal cancer - A case report
42. Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats
43. Protective effects of Kampo medicine and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats
44. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride
45. Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of anticancer agent, irinotecan hydrochloride (CPT-11) in rats
46. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research groups of CPT-11 in Gynecologic Cancers
47. Phase I and pharmacokinetic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients
48. CPT-11 converting enzyme from rat serum: Purification and some properties
49. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon